TDOC

Teladoc is the case of a fallen growth name now trading like a distressed value stock, and the truth sits in between. Revenue has flatlined and is now slipping — $2.53B in FY2025, down 1.5% YoY and below the FY2023 peak of $2.60B — which is the core problem: the virtual-care land-grab is over and TDOC is no longer growing. The 10-K's own 'Key Factors' admit the membership mix is deteriorating, as higher-margin paid-access members give way to visit-fee-only access, and that health plans 'have developed, and may in the future continue to develop, solutions that replicate our services,' i.e. its own channel partners are becoming competitors. Layer on heavy client concentration (top-five clients are a 'substantial portion' of revenue) and you have a business with a shrinking top line and structural competitive pressure.

That said, the company is not the GAAP-loss disaster the headline -$200M net loss suggests. The 2025 loss includes a $71.8M non-cash goodwill impairment, and more importantly operating cash flow was a solid +$294M against just $8.9M of capex — roughly $285M of free cash flow on a $1.55B market cap. The GAAP losses are largely non-cash (D&A, stock comp, impairments). The balance sheet is serviceable: $781M cash, liabilities/equity of only 1.06x, and current assets ($1.12B) covering current liabilities ($405M) ~2.8x. So this is a cash-generative business priced at ~0.6x sales and a low-single-digit multiple of operating cash flow — genuinely cheap.